Evidence map›Paper›PMID 39819342›Full record

ArticleFuture medicinal chemistry2025

Dual VEGFR-2 and EGFR

Marwa Alsulaimany, Ahmed K B Aljohani, Nour E A Abd El-Sattar, Sara A Almadani, Omar M Alatawi, Hussam Y Alharbi, Majed S Aljohani, Adel H Al-Shareef, Read Alghamdi, Saeed M Tayeb and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Future medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Marwa AlsulaimanyDepartment of Pharmacognosy & Pharmaceutical Chemistry, College of Pharmacy, Taibah University, Medina, Saudi Arabia.
Ahmed K B AljohaniPharmacognosy and Pharmaceutical Chemistry Department, College of Pharmacy, Taibah University, Al-Madinah Al-Munawarah, Saudi Arabia.
Nour E A Abd El-SattarDepartment of Chemistry, Faculty of Science, Ain Shams University, Cairo, Egypt.
Sara A AlmadaniDepartment of Pharmacology and Toxicology, College of Pharmacy, Taibah University, Medina, Saudi Arabia.
Omar M AlatawiDepartment of Chemistry, Faculty of Science, University of Tabuk, Tabuk, Saudi Arabia.
Hussam Y AlharbiDepartment of Chemistry, Faculty of Science, Taibah University, Yanbu, Saudi Arabia.
Majed S AljohaniDepartment of Chemistry, Faculty of Science, Taibah University, Yanbu, Saudi Arabia.
Adel H Al-ShareefDepartment of Chemistry, College of Science, University of Jeddah, Jeddah, Saudi Arabia.
Read AlghamdiPharmacognosy and Pharmaceutical Chemistry Department, College of Pharmacy, Taibah University, Al-Madinah Al-Munawarah, Saudi Arabia.
Saeed M TayebDepartment of Pharmaceutical Science, College of Pharmacy, Umm Al-Qura University, Makkah, Saudi Arabia.
Doaa E KeshekDepartment of biology, Al-Jumum College University, Umm Al-Qura University, Makkah, Sudia Arabia.
Khaled El-AdlPharmaceutical Chemistry Department, Faculty of Pharmacy, Heliopolis University for Sustainable Development, Cairo, Egypt.ORCID 0000-0002-8922-9770
Kurls E AnwerDepartment of Chemistry, Faculty of Science, Ain Shams University, Cairo, Egypt.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimNew phenyldiazene scaffold-linked heterocyclic pyrazole, pyrimidinone, pyrimidinthione, and/or triazine rings have been developed and synthesized. METHODS &

resultsCytotoxicity of our derivatives was estimated on four cancer and VERO normal cell lines targeting EGFR

conclusionOur derivatives could be considered as anticancer agents with dual VEGFR-2 and EGFR

Indexed as

Antineoplastic AgentsDrug DesignErbB ReceptorsProtein Kinase InhibitorsVascular Endothelial Growth Factor Receptor-2AnimalsCell Line, TumorCell ProliferationChlorocebus aethiopsDose-Response Relationship, DrugDrug Screening Assays, AntitumorHumansMolecular Docking SimulationMolecular StructureStructure-Activity RelationshipVero CellsAntineoplastic AgentsEGFR protein, humanErbB ReceptorsKDR protein, humanProtein Kinase InhibitorsVascular Endothelial Growth Factor Receptor-2ADMETdockingdual inhibitorsEGFRT790MPhenyldiazenesVEGFR-2

Identifiers

PMID39819342
PMCPMC11792794

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.